Japan Approves the World’s First Drug to Treat Parkinson’s Disease

Japan’s Minister of Health, Kenichiro Ueno, announced the official approval for the production and sale of the drug “Amshepuri”, a groundbreaking treatment for Parkinson’s disease that relies on transplanting nerve cells cultivated from induced pluripotent stem cells (iPS).

According to RT Arabic, the approval follows the major success of clinical trials conducted in April 2025, which showed noticeable improvement in patients. These results prompted Japanese authorities to adopt an accelerated review process for this innovation developed by Kyoto University in collaboration with Sumitomo Pharma.

In the same context, the minister explained that the approval also includes the drug “Reheart”, designed to treat ischemic cardiomyopathy. He emphasized that both medications are unique worldwide and represent a scientific breakthrough that began with the 2012 Nobel Prize awarded to scientist Shinya Yamanaka.

This achievement paves the way for the use of regenerative medicine to potentially provide definitive treatments for incurable diseases, offering hope to millions of patients around the world.